49600-34-2

Basic information

• Product Name: (6-METHYL-PYRIDIN-2-YL)-THIOUREA
• Synonyms: (6-METHYL-PYRIDIN-2-YL)-THIOUREA;N-(6-Methyl-2-pyridyl)thiourea, 97%;1-(6-methylpyridin-2-yl)thiourea;N-(6-Methylpyridin-2-yl)thiourea
• CAS NO: 49600-34-2
• Molecular Formula: C₇H₉N₃S
• Molecular Weight: 167.23
• Mol File: 49600-34-2.mol
• Article Data: 9

Chemical Properties

• Melting Point: 193-197℃
• Boiling Point: 295.3 °C at 760 mmHg
• Flash Point: 132.4 °C
• Appearance: /
• Density: 1.316 g/cm³
• Vapor Pressure: 0.00154mmHg at 25°C
• Refractive Index: 1.709
• CAS DataBase Reference: (6-METHYL-PYRIDIN-2-YL)-THIOUREA(CAS DataBase Reference)
• NIST Chemistry Reference: (6-METHYL-PYRIDIN-2-YL)-THIOUREA(49600-34-2)
• EPA Substance Registry System: (6-METHYL-PYRIDIN-2-YL)-THIOUREA(49600-34-2)

Safety Data

• Hazardous Substances Data: 49600-34-2(Hazardous Substances Data)

Usage

General Description

(6-Methyl-pyridin-2-yl)-thiourea is a chemical compound with the molecular formula C7H9N3S. It is a member of the thiourea family, which are organic compounds containing a carbon-to-sulfur double bond. This particular compound contains a methyl-substituted pyridine ring, which gives it unique aromatic properties. Thioureas have been studied for their potential biological and industrial applications, including their use as catalysts, anti-thyroid drugs, and herbicides. The specific properties and potential uses of (6-Methyl-pyridin-2-yl)-thiourea would depend on its specific chemical and physical properties, as well as its potential interactions with other compounds and biological systems.

InChI:InChI=1/C7H9N3S/c1-5-3-2-4-6(9-5)10-7(8)11/h2-4H,1H3,(H3,8,9,10,11)

Upstream product

• 1824-81-3 2-Amino-6-methylpyridine 
• 1147550-11-5 ammonium thiocyanate 
• 96938-51-1 N-(6-methylpyridine-2-ylcarbamothioyl)benzamide 
• 532-55-8 Benzoyl isothiocyanate 
• 53385-83-4 N-(3-methylpyridin-2-yl)-N'-phenyl-thiourea 

Downstream Products

• 861883-81-0 3-[5-bromo-2-(6-methyl-pyridin-2-ylamino)-thiazol-4-yl]-benzonitrile 
• 1269603-80-6 (4S)-4-(N-benzyloxycarbonyl-2-aminoethyl)-2-[(6-methylpyridyl-2)amino]imidazoline 
• 1049119-53-0 C₁₇H₁₇N₃S 
• 1266676-92-9 (6-methylpyridin-2-yl)-[4-(3-phenylisoxazol-5-yl)-thiazol-2-yl]-amine 
• 708283-68-5 [4-(3,4-dimethoxyphenyl)-thiazol-2-yl]-(6-methylpyridin-2-yl)-amine 
• 1426259-33-7 (6-methylpyridin-2-yl)-[4-(4-pyridin-4-yl-phenyl)thiazol-2-yl]amine 
• 1426259-70-2 4-(4-{2-[(6-methylpyridin-2-yl)amino]thiazol-4-yl}phenyl)pyridine 1-oxide 
• 1426259-78-0 (6-methylpyridin-2-yl)-{4-[4-(3-methylpyridin-4-yl)phenyl]thiazol-2-yl}amine trifluoroacetate 
• 1426259-35-9 (6-methylpyridin-2-yl)-[4-(4-pyridin-3-yl-phenyl)thiazol-2-yl]amine 
• 1426259-51-9 3-(4-{2-[(6-methylpyridin-2-yl)amino]-1,3-thiazol-4-yl}phenyl)pyridin-1-ium-1-olate 
• 1448015-73-3 (6-Methylpyridin-2-yl)-{4-[4-(2-methylpyridin-3-yl)phenyl]thiazol-2-yl}amine trifluoroacetate salt 

Relevant articles and documents

2-Aminothiazoles with Improved Pharmacotherapeutic Properties for Treatment of Prion Disease

Recently, we described the aminothiazole lead (4-biphenyl-4-ylthiazol-2-yl)-(6-methylpyridin-2-yl)-amine (1), which exhibits many desirable properties, including excellent stability in liver microsomes, oral bioavailability of ～40%, and high exposure in the brains of mice. Despite its good pharmacokinetic properties, compound 1 exhibited only modest potency in mouse neuroblastoma cells overexpressing the disease-causing prion protein PrPSc. Accordingly, we sought to identify analogues of 1 with improved antiprion potency in ScN2a-cl3 cells while retaining similar or superior properties. Herein we report the discovery of improved lead compounds such as (6-methylpyridin-2-yl)-[4-(4-pyridin-3-yl-phenyl)thiazol-2-yl]amine and cyclopropanecarboxylic acid (4-biphenylthiazol-2-yl)amide, which exhibit brain exposure/EC50 ratios at least tenfold greater than that of compound 1.

NOVEL ANTIPRION COMPOUNDS

Described herein are novel compositions and methods of treatment addressing diseases such as neurodegenerative diseases, including prion diseases and Alzheimer's disease.

New imidazoline/α2-adrenoceptors affecting compounds-4(5)-(2-aminoethyl)imidazoline (dihydrohistamine) derivatives. Synthesis and receptor affinity studies

Compilation of agmatine structure and imidazoline moiety leads to a new group of imidazoline/α2-adrenoceptor ligands, 4(5)-(2-aminoethyl)imidazoline derivatives. In this study the exploration of previously unknown 4(5)-(2-aminoethyl)imidazolines including the analogues of reported imidazoline and α2-aderenoceptors ligands: clonidine, rilmenidine, idazoxan, efaroxan, antazoline, tracizoline is described. The synthesis of a variety of novel 4(5)-(2-aminoethyl)imidazolines and their I 1, I2, α2-adrenoceptors affinities are reported.